Spinal cord repair: could cell injections restore function in transverse myelitis?
NCT ID NCT03887273
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of injecting Q-Cells, a type of human glial progenitor cell, directly into spinal cord lesions in people with transverse myelitis. The study enrolls up to 9 adults aged 18–70 who have had the condition for at least 3 months. Researchers will monitor side effects and measure changes in motor and sensory function to see if the cells are safe and show any signs of activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Q-Cells (glial restricted progenitor cells) injected into the spinal cord
- What this could lead to
- If safe and effective, this approach could help repair damaged spinal cord tissue and improve motor and sensory function in people with transverse myelitis.
- What could go wrong
- This is an early, small trial focused on safety, not yet on effectiveness. The injection procedure itself carries risks, and the cells may not produce meaningful improvement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSVERSE MYELITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Researchers hunt for clues: do our own antibodies harm nerves?
- 10-Year watch begins for experimental spinal cord therapy
- Scientists launch major effort to unravel mysteries of rare brain and spinal cord diseases
- Pen and paper therapy: could expressive writing ease grief after spinal cord injury?
- Massive biobank launches to unlock secrets of MS and related disorders